Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx Inc (NASDAQ: ARDX) is a biopharmaceutical company pioneering first-in-class therapies for renal and gastrointestinal disorders. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Discover official press releases covering tenapanor developments, hyperphosphatemia research breakthroughs, and international collaboration updates with partners in Japan and China. Our curated collection includes financial results, manufacturing announcements, and expert analyses of ARDX's novel drug discovery platform.
Key content categories include FDA regulatory updates, phase 3 clinical trial results, partnership expansions, and financial performance reports. All materials maintain strict compliance with financial disclosure regulations while presenting complex medical information in accessible language.
Bookmark this page for real-time updates on ARDX's progress in developing treatments for chronic kidney disease and IBS-C. Regularly refreshed content ensures you stay informed about this innovative biotech leader's contributions to renal care and gastrointestinal health.
Ardelyx (ARDX) reported strong financial results for FY 2024, with total revenue reaching $333.6 million, including $319.2 million in U.S. Net Product Sales. IBSRELA achieved $158.3 million in net product sales, while XPHOZAH recorded $160.9 million in its first full year of commercialization.
The company ended 2024 with $250.1 million in cash and investments, up from $184.3 million in 2023. Net loss for 2024 was $39.1 million ($0.17 per share), improved from $66.1 million ($0.30 per share) in 2023. Ardelyx reaffirms combined peak sales expectations of $1.75 billion for both products, with IBSRELA projected to achieve over $1 billion and XPHOZAH expected to reach $750 million in annual U.S. net product sales before patent expiration.
Ardelyx (ARDX) has announced its upcoming participation at TD Cowen's 45th Annual Health Care Conference. The company's management will deliver a presentation on Monday, March 3, 2025, at 9:50am ET in Boston.
The presentation will be accessible via live webcast through the Events and Presentations page on Ardelyx's investor relations website. Interested parties can view a replay of the panel presentation on the company's website for 30 days following the event.
Ardelyx is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines addressing significant unmet medical needs.
Ardelyx (ARDX) has scheduled a conference call for Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss its full year and fourth quarter 2024 financial results and provide a business update. Participants can join via phone by dialing (877) 346-6112 (domestic) or (848) 280-6350 (international). The call will also be webcast live on the company's website under the Investors section, with a replay available for 30 days following the call.
Ardelyx (ARDX) reported strong commercial performance for 2024, with total U.S. net product sales of approximately $319 million. IBSRELA achieved approximately $158 million in net product sales, with $54 million in Q4 alone. The company expects 2025 IBSRELA sales between $240-250 million, reaffirming its peak sales potential of over $1 billion.
XPHOZAH recorded approximately $161 million in net product sales during its first full year, including $57 million in Q4. The company projects peak annual sales of $750 million for XPHOZAH. As of December 31, 2024, Ardelyx maintained a strong financial position with approximately $250 million in cash, cash equivalents, and investments, with approximately 238 million shares outstanding.
Ardelyx, a biopharmaceutical company, announced that its President and CEO, Mike Raab, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025 at 4:30pm PT in San Francisco.
Ardelyx is focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs. Interested parties can access the live webcast of the presentation on the Ardelyx website. A replay will be available for 30 days post-event.
Ardelyx (ARDX) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's Chief Financial and Operations Officer, Justin Renz, and Chief Commercial Officer, Eric Foster, will engage in a fireside chat on Wednesday, December 4, 2024, at 12:30pm EST in New York City.
The presentation will be accessible via live webcast on the Events and Presentations page of Ardelyx's website, with a replay available for 30 days following the event.
Ardelyx (ARDX) faces a setback as the U.S. District Court dismisses their lawsuit against CMS's decision to include oral-only phosphate-lowering therapies in the ESRD PPS starting January 1, 2025. This decision affects XPHOZAH, Ardelyx's FDA-approved therapy for reducing serum phosphorus in adults with chronic kidney disease on dialysis. The company argues this inclusion in the bundled payment system will restrict patient access to essential medications. CEO Mike Raab expressed disappointment, stating the decision could harm dialysis patients' access to optimal care. Ardelyx is reviewing the court's decision and considering all legal options while urging Congress to pass the Kidney PATIENT Act.
Ardelyx (ARDX) has announced its participation in the 2024 Jefferies London Healthcare Conference. The company's leadership team, including President and CEO Michael Raab, CFO Justin Renz, and CCO Eric Foster, will engage in a fireside chat on Tuesday, November 19, 2024, at 12:30pm GMT / 7:30am EST in London.
The presentation will be accessible via live webcast on the Events and Presentations page of Ardelyx's website, with a replay available for 30 days following the event.
Ardelyx (ARDX) reported strong Q3 2024 financial results, with IBSRELA generating $40.6 million in net product sales (15% quarter-over-quarter growth) and XPHOZAH achieving $51.5 million (39% quarter-over-quarter growth). Total revenue reached $98.2 million, compared to $56.4 million in Q3 2023. The company ended Q3 with $190.4 million in cash and investments. Ardelyx expects full-year 2024 IBSRELA net sales to be between $145-150 million. The company secured additional financing through an amended loan agreement with SLR Capital Partners, drawing $50 million with the option for an additional $50 million.
Ardelyx (ARDX) presented results from its IBS in America 2024 supplemental survey at the American College of Gastroenterology's Annual Meeting. The nationwide online survey of over 280 IBS-C patients revealed significant impacts on quality of life, with 90% reporting negative effects on mental, emotional, and sexual health, relationships, and independence.
Key findings show that 85% of patients experienced rectal pain during bowel movements, 86% reported bloating, and 85% suffered from abdominal cramps. Over 45% of patients considered IBS-C a financial hardship. Among perimenopausal or menstruating respondents, over 80% reported menstruation worsened abdominal pain and bloating symptoms.
FAQ
What is the current stock price of Ardelyx (ARDX)?
What is the market cap of Ardelyx (ARDX)?
